Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-20-000185
Filing Date
2020-03-05
Accepted
2020-03-04 19:26:44
Documents
2
Group Members
ORBIMED CAPITAL GP V LLCORBIMED CAPITAL LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 13 ss168177_sc13da.htm SC 13D/A 121621
2 JOINT FILING AGREEMENT ss168177_ex9901.htm EX-99.1 8528
  Complete submission text file 0000947871-20-000185.txt   131677
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900
Business Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900 45 70 22 22 44
Ascendis Pharma A/S (Subject) CIK: 0001612042 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88586 | Film No.: 20689095
SIC: 2834 Pharmaceutical Preparations